Invasive Tracheobronchial Aspergillosis in a Lung Transplant Recipient Receiving Belatacept as Salvage Maintenance Immunosuppression: A Case Report

Transplant Proc. 2016 Jan-Feb;48(1):275-8. doi: 10.1016/j.transproceed.2016.01.003.

Abstract

Introduction: The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear.

Case report: We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation.

Conclusions: Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation.

Publication types

  • Case Reports

MeSH terms

  • Abatacept / adverse effects*
  • Female
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / adverse effects*
  • Invasive Pulmonary Aspergillosis / chemically induced*
  • Invasive Pulmonary Aspergillosis / pathology
  • Lung Transplantation*
  • Middle Aged
  • Salvage Therapy / adverse effects*
  • Salvage Therapy / methods
  • Trachea / microbiology

Substances

  • Immunosuppressive Agents
  • Abatacept